Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: a PIDTC study.

  • Read more about Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: a PIDTC study.

JAK-inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID and EBMT IEWP retrospective study.

  • Read more about JAK-inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID and EBMT IEWP retrospective study.

Post-Transplant Late Complications Increase Over Time for Patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) Landmark Study.

  • Read more about Post-Transplant Late Complications Increase Over Time for Patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) Landmark Study.

Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease.

  • Read more about Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease.

Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy.

  • Read more about Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy.

Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy.

  • Read more about Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy.

NFKB2 haploinsufficiency identified via screening for IFNa2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2-related complications.

  • Read more about NFKB2 haploinsufficiency identified via screening for IFNa2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2-related complications.

The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions.

  • Read more about The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions.

The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions.

  • Read more about The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions.

Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A�randomized controlled trial.

  • Read more about Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A�randomized controlled trial.

Pagination

  • Page 1
  • Next page ››
Subscribe to The Journal of allergy and clinical immunology

Pediatrics Home

MAKE A GIFT

© 2022 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                              Accessibility  Privacy Policy  Terms of Use  A-Z Website List